ARQT

Arcutis Biotherapeutics, Inc.

October 19, 2026 · pre-market

Rarity

1.72

Peak move

+11.37%

Float cap

$3.1B

Still running — rarity and peak move can only rise from here.

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological diseases. It markets ZORYVE cream and foam, once-daily steroid-free PDE4 inhibitors, for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in adults and pediatric patients. It sells primarily to dermatology and primary care prescribers and patients in the United States and Canada, with licensing partners in Greater China, Southeast Asia, and Japan.